Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘Geriatric medicine’ Category

WHO asks dozens of journals to correct papers on diagnostic tool developed by former collaborators

with 3 comments

In one of the largest such requests we’ve ever heard of, the World Health Organization has asked 46 journals to correct articles that refer to a bone fracture risk diagnostic tool as developed or endorsed by the WHO.

By WHO’s count, the tool — known as Fracture Risk Assessment Tool (FRAX), which has come under scrutiny as experts have questioned its effectiveness — has been linked to the WHO in over 500 scientific articles. The organization wants to change that. The health agency says it has no ties to the tool and claims its developers have spread “misinformation” asserting a link to the WHO. But the tool’s lead developer disputes this, claiming the agency collaborated on the tool from its inception.

Last December, in an editorial published in the Bulletin of the World Health Organization titled “Clarifying WHO’s position on the FRAX tool for fracture prediction,” the organization disavowed a connection to the tool:

Read the rest of this entry »

Written by Mark Zastrow

November 16th, 2017 at 11:10 am

Posted in Geriatric medicine

Bone researcher is up to 17 retractions

with 4 comments

A bone researcher has lost three more papers for scientific misconduct.

The new retractions bring Yoshihiro Sato’s total to 17 and put him on our Leaderboard.

According to the retraction notices, Sato asked the Journal of Neurology, Neurosurgery, and Psychiatry to retract three of his papers “due to scientific misconduct.” In the letter, Sato—who is corresponding author on all three papers—explained he included co-authors without their consent and that none of the other authors listed worked on the study or article.

In May, the editors issued expressions of concern while they investigated (1, 2, 3), and last month, the journal retracted the three articles.

Here’s the retraction notice for “Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease:” Read the rest of this entry »

JAMA tells readers: “Caution advised.” Here’s why.

with 8 comments

Last week, JAMA issued some unusual notices, letting readers know they should use caution when reading an editorial and letters associated with now-retracted articles by a bone researcher in Japan.

The notices — for papers by Yoshihiro Sato, now up to 14 retractions — remind readers not to heed the results of the now-retracted papers, and alert them to read any associated materials (specifically, an editorial in JAMA and letters in JAMA Internal Medicine) with caution.

The text of the notices describes them as “formal correction notices;” we asked Annette Flanagin, executive managing editor at The JAMA Network, why they chose that approach, instead of an expression of concern or retraction:

Read the rest of this entry »

Journal retracts two papers by authors who lifted others’ data

without comments

A journal has retracted two 2014 papers after the editors discovered the authors used data from other research groups without permission.

The papers, both published in the same issue of Cell Biochemistry and Biophysics and retracted in May, suffered from similar issues—the authors published data that was not theirs. The authors are all based at different institutions in China; as far as we can tell, the papers do not have any authors in common.

When we asked the publisher whether a third party, such as a paper mill, may have been involved, a spokesperson for Springer told us: Read the rest of this entry »

A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

with one comment

Last year, a researcher cast doubt on a bone scientist’s clinical trials, suggesting some of the findings may not be legitimate. So what’s happened since?

Since 2015, journals have retracted 14 papers by bone researcher Yoshihiro Sato, based at Mitate Hospital in Japan, for issues ranging from self-plagiarism, to problems with data, to including co-authors without their consent. (We covered the latest two retractions this week.) Last year’s analysis identified patterns in more than 30 of Sato’s clinical trials that suggest systematic problems with the results. (Sato has defended his research.)

With doubts cast on Sato’s body of work, we contacted the journals that have published his papers involving human trials, to see if any taken another look at Sato’s work; several responded. While most believe there is little reason to take further action at this time, some told us they are investigating.
Read the rest of this entry »

Fraud by bone researcher takes down two meta-analyses, a clinical trial, and review

with 4 comments

The troubles continue for a bone researcher, who’s lost multiple papers in recent months due to problems ranging from data issues to including authors without their consent.

Now, journals have retracted two more papers by Yoshihiro Sato. And in a sign of the downstream effects that fraud can have, another journal has retracted two meta-analyses by other authors that cited his work.

Earlier this month, the journal Current Medical Research and Opinion retracted the two meta-analyses because they were based on recently retracted papers by Sato, affiliated with Mitate Hospital. The two new retractions of Sato’s papers are a review and a randomized controlled trial.

Sato was not an author on the meta-analyses published in 2008 and 2011; he was, however, first and lead author on all the retracted papers referenced in the notices. The notices state that the trio of authors on the meta-analyses:

Read the rest of this entry »

Bone researcher with lifetime funding ban earns third retraction

without comments

via WCH

A researcher who received a lifetime funding ban for misconduct from a Canadian agency has logged her third retraction, after a re-analysis of her work unveiled “serious inconsistencies.”

In July, the Canadian Institutes of Health Research (CIHR) released a report about Sophie Jamal, following an investigation by her former employer, The Women’s College Hospital in Toronto, Canada. The probe concluded that Jamal had manipulated data, which resulted in her being banned from CIHR funding for life, and the retraction of a study in The Journal of the American Medical Association.

After that retraction, researchers that made up the the Canadian Multicentre Osteoporosis Study Group (CaMos) decided to take a second look at Jamal’s work. In August, we reported on a retraction that came out of that examination, in the American Journal of Kidney Diseases (AJKD). At the time, a senior researcher from the group told us the group had also requested another journal retract a CaMos paper. 

Now, that other retraction has appeared. Here’s the retraction notice Osteoporosis International issued earlier this month: Read the rest of this entry »

Scientific publisher hacked, affecting 65 papers

with 2 comments

kowsar-publishingA publisher in the Netherlands has retracted 13 published studies and withdrawn 52 that were under consideration (but not yet published) after learning that someone illegally accessed its workflows to add fake authors and manipulate text.

According to Seyyed Mohammad Miri, the founder, CEO, and managing director of Kowsar Publishing, the 13 retracted papers all included extra authors added by the same Internet Protocol (IP) address. Cyber police in Iran found the same IP address had also accessed the 52 other papers, which were in various stages of the publishing process (such as peer review) and not yet online, Miri told Retraction Watch. 

Most of the authors on the 13 retracted papers are based in institutions in Iran; some were co-authors on the 58 retractions recently issued as part of a mass clean-up by publishers BioMed Central and Springer, citing fake reviews, adding inappropriate authors, and plagiarism.

Around six or seven months ago, the affected journals — in collaboration with Kowsar, their publisher — filed a court case in Tehran, Iran against this IP address, Miri said. Read the rest of this entry »

Analysis casts doubt on bone researcher’s body of work

with 3 comments

19-coverA new analysis of more than 30 clinical trials co-authored by a bone researcher based in Japan is casting doubt on the legitimacy of the findings.

Yoshihiro Sato, based at Mitate Hospital, has already retracted 12 papers, for reasons ranging from data problems, to including co-authors without their consent, to self-plagiarism. Most of these retracted papers are included in the analysis in the journal Neurology, which concluded that Sato’s 33 randomized clinical trials exhibited patterns that suggest systematic problems with the results.

Other researchers have used similar approaches to analyze a researcher’s body of work — notably, when John Carlisle applied statistical tools to uncover problems in the research of notorious fraudster Yoshitaka Fujii, and Uri Simonsohn, who sniffed out problems with the work of social psychologist  Dirk Smeesters.

Author Mark Bolland of the University of Auckland told us he was surprised by his findings: Read the rest of this entry »

Written by Alison McCook

November 9th, 2016 at 4:00 pm

Despite retraction, antipsychotics still effective, safe for dementia, says author

without comments

alzheimers-research-and-therapyResearchers have retracted a systematic review that suggested that antipsychotic drugs are effective and safe for patients with symptoms of dementia — but claim their re-analysis of the updated data still comes to the same conclusions.

According to the retraction notice in Alzheimer’s Research and Therapy, some participants were incorrectly included twice in the meta-analysis. 

The corresponding authors recently lost another paper for an entirely different reason — earlier this year, we reported on a retraction in Annals of Neurology for Jin-Tai Yu and Lan Tanaffiliated with the Ocean University of China, Qingdao University, and Nanjing Medical University in China. The authors pulled that paper after appearing to pass off others’ data as their own.

Here’s the retraction notice for the review, issued earlier this year: Read the rest of this entry »